This study is examining a medicine called fruquintinib for people with advanced colorectal cancer who are Black, African American, Hispanic, or Latino. Colorectal cancer is a cancer that starts in the colon or rectum. The study is checking if these minority groups have a higher risk of getting high blood pressure, a known side effect of fruquintinib. Currently, it’s unclear if these groups are more affected than others. Participants will take fruquintinib in 4-week cycles until their condition worsens or they can't tolerate it. After stopping treatment, they will have check-ups every 3 months.

• Participants need to be 18 or older and have previously tried standard cancer treatments.
• They will need to identify as Black, African American, Hispanic, or Latino.
• Participants will be followed closely for safety and how well they manage the treatment.

People with certain health conditions like uncontrolled high blood pressure or recent heart issues cannot join. Participants should be ready for regular doctor visits and follow safety instructions throughout the study.